Valiant Laboratories Limited — Others, 13-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Valiant Laboratories has announced a board meeting to discuss the financial results for the quarter and half-year. The company confirmed that there is no deviation or variation in the utilization of the ₹152 crore raised from its IPO during the quarter ended September 30, 2024. The Monitoring Agency, CARE Ratings Limited, has verified the full use of proceeds for the intended purposes. This transparency reinforces investor confidence and suggests a positive outlook, as the company efficiently executes its capital allocation strategy without any issues.